{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T17:48:43Z","timestamp":1761155323784,"version":"3.44.0"},"reference-count":70,"publisher":"MJS Publishing, Medical Journals Sweden AB","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Oncologica"],"published-print":{"date-parts":[[2005,5]]},"DOI":"10.1080\/02841860510029644","type":"journal-article","created":{"date-parts":[[2009,12,9]],"date-time":"2009-12-09T08:04:26Z","timestamp":1260345866000},"page":"282-292","source":"Crossref","is-referenced-by-count":20,"title":["Skeletal complications of prostate cancer: Pathophysiology and therapeutic potential of bisphosphonates"],"prefix":"10.2340","volume":"44","author":[{"given":"Jonathan R.","family":"Green","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1183","published-online":{"date-parts":[[2009,7,8]]},"reference":[{"key":"CIT0002","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","volume":"27","author":"Coleman RE","year":"2001","journal-title":"Cancer Treat Rev"},{"key":"CIT0003","first-page":"2008","volume":"169","author":"Smith MR","year":"2003","journal-title":"Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol"},{"key":"CIT0004","first-page":"2927","volume":"22","author":"Loblaw DA","year":"2004","journal-title":"American Society of Clinical Oncology recommendations for the initial hormonal man-agement of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Chin Oncol"},{"key":"CIT0005","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/1097-0045(2000)45:10+<38::AID-PROS8>3.0.CO;2-M","volume":"10","author":"Stege R","year":"2000","journal-title":"Prostate Suppl"},{"key":"CIT0006","first-page":"892","volume":"100","author":"Diamond TH","year":"2004","journal-title":"Singer FR. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diag-nosis and therapies. Cancer"},{"key":"CIT0008","first-page":"167b","volume":"20","author":"Modi S","year":"2001","journal-title":"Proc Am Soc Chin Oncol"},{"key":"CIT0009","first-page":"382","volume":"23","author":"Smith MR","year":"2004","journal-title":"Proc Am Soc Chin Oncol"},{"key":"CIT0010","first-page":"726","volume":"23","author":"Krupski TL","year":"2004","journal-title":"Proc Am Soc Chin Oncol"},{"key":"CIT0011","first-page":"2705","volume":"10","author":"Michaelson MD","year":"2004","journal-title":"Contribution of androgen deprivation therapy to elevated osteoclast activity in men with metastatic prostate cancer. Clin Cancer Res"},{"doi-asserted-by":"publisher","key":"CIT0012","DOI":"10.1210\/jcem.87.8.8782"},{"doi-asserted-by":"publisher","key":"CIT0013","DOI":"10.1359\/jbmr.1998.13.11.1775"},{"key":"CIT0014","doi-asserted-by":"crossref","first-page":"18","DOI":"10.22203\/eCM.v001a03","volume":"1","author":"Glatt M","year":"2001","journal-title":"Eur Cell Mater"},{"key":"CIT0015","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00223-002-2015-4","volume":"72","author":"Hornby SB","year":"2003","journal-title":"Calcif Tissue hit"},{"key":"CIT0016","first-page":"707","volume":"15","author":"Glatt M","year":"2004","journal-title":"Loss of vertebral bone and mechanical strength in estrogen-deficient rats is prevented by long-term administration of zole-dronic acid. Osteoporos Int"},{"issue":"1","key":"CIT0019","first-page":"S473","volume":"12","author":"O'Rourke C","year":"1997","journal-title":"J Bone Miner Res"},{"doi-asserted-by":"publisher","key":"CIT0020","DOI":"10.1056\/NEJMoa010845"},{"doi-asserted-by":"publisher","key":"CIT0021","DOI":"10.1016\/S0022-5347(05)64561-2"},{"key":"CIT0022","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/clinchem\/41.10.1489","volume":"41","author":"Demers LM","year":"1995","journal-title":"Clin Chem"},{"doi-asserted-by":"publisher","key":"CIT0023","DOI":"10.1054\/bjoc.1999.1012"},{"key":"CIT0024","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jnci\/dji002","volume":"97","author":"Brown JE","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"CIT0025","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S1569-9056(04)90609-4","volume":"3","author":"Saad F","year":"2004","journal-title":"Eur Urol Suppl"},{"key":"CIT0026","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","volume":"88","author":"Lipton A","year":"2000","journal-title":"Cancer"},{"doi-asserted-by":"publisher","key":"CIT0027","DOI":"10.1002\/cncr.20308"},{"key":"CIT0028","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","volume":"96","author":"Saad F","year":"2004","journal-title":"J Natl Can-cer Inst"},{"issue":"5","key":"CIT0029","first-page":"180","volume":"13","author":"Weinfurt KP","year":"2002","journal-title":"Ann Oncol"},{"key":"CIT0030","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0022-5347(17)40597-0","volume":"141","author":"Smith JA Jr","year":"1989","journal-title":"J Urol"},{"key":"CIT0031","first-page":"159","volume":"24","author":"Elomaa I","year":"1992","journal-title":"A controlled study in patients with metastatic prostatic cancer. Int Urol Nephrol"},{"key":"CIT0032","first-page":"939","volume":"76","author":"Kylm\u00e4ld T","year":"1997","journal-title":"Concomitant i.v. and oral clodronate in the relief of bone pain-a double-blind placebo-controlled study in patients with prostate cancer. Br J Cancer"},{"key":"CIT0033","first-page":"4717","volume":"17","author":"Strang P","year":"1997","journal-title":"Anticancer Res"},{"key":"CIT0034","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1200\/JCO.2003.03.042","volume":"21","author":"Ernst DS","year":"2003","journal-title":"J Clin Oncol"},{"key":"CIT0035","first-page":"4277","volume":"21","author":"Small EJ","year":"2003","journal-title":"Combined analysis of two multicenter, randomized, pla-cebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol"},{"key":"CIT0036","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/jnci\/djg038","volume":"95","author":"Dearnaley DP","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"CIT0037","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","volume":"94","author":"Saad F","year":"2002","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"CIT0038","first-page":"14","volume":"11","author":"Green J","year":"2000","journal-title":"Ann Oncol"},{"doi-asserted-by":"publisher","key":"CIT0039","DOI":"10.1046\/j.1365-2141.2002.03257.x"},{"key":"CIT0040","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1359\/jbmr.2003.18.3.482","volume":"18","author":"Croucher PI","year":"2003","journal-title":"J Bone Miner Res"},{"key":"CIT0041","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/sj.leu.2400892","volume":"12","author":"Aparicio A","year":"1998","journal-title":"Leukemia"},{"key":"CIT0042","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1359\/jbmr.1999.14.12.2048","volume":"14","author":"Derenne S","year":"1999","journal-title":"J Bone Miner Res"},{"key":"CIT0043","first-page":"4418","volume":"61","author":"Hiraga T","year":"2001","journal-title":"Cancer Res"},{"key":"CIT0044","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1054\/bjoc.2000.1679","volume":"84","author":"Mackie PS","year":"2001","journal-title":"Br J Cancer"},{"key":"CIT0045","first-page":"1459","volume":"82","author":"Senarame SG","year":"2000","journal-title":"Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer"},{"key":"CIT0046","first-page":"665","volume":"98","author":"Shipman CM","year":"1997","journal-title":"Croucher PI. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol"},{"key":"CIT0048","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/00001813-200106000-00007","volume":"12","author":"Sonnemann J","year":"2001","journal-title":"Anticancer Drugs"},{"doi-asserted-by":"publisher","key":"CIT0049","DOI":"10.1016\/S0145-2126(00)00087-4"},{"key":"CIT0050","first-page":"956","volume":"43","author":"Tassone P","year":"2002","journal-title":"Proc Am Assoc Cancer Res"},{"key":"CIT0051","first-page":"1574","volume":"9","author":"Corey E","year":"2003","journal-title":"Clin Cancer Res 2003; 9: 295-306. [Published erratum appears in Chin Cancer Res"},{"key":"CIT0052","first-page":"2602","volume":"61","author":"Lee MV","year":"2001","journal-title":"Cancer Res"},{"key":"CIT0053","first-page":"2949","volume":"60","author":"Boissier S","year":"2000","journal-title":"Cancer Res"},{"key":"CIT0054","first-page":"3890","volume":"57","author":"Boissier S","year":"1997","journal-title":"Cancer Res"},{"doi-asserted-by":"publisher","key":"CIT0055","DOI":"10.1002\/(SICI)1097-0215(19991008)83:2<263::AID-IJC19>3.0.CO;2-T"},{"key":"CIT0056","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1172\/JCI118841","volume":"98","author":"van der Pluijm G","year":"1996","journal-title":"J Chin Invest"},{"key":"CIT0057","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/jpet.102.035295","volume":"302","author":"Wood J","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"CIT0058","first-page":"6538","volume":"62","author":"Fournier P","year":"2002","journal-title":"Cancer Res"},{"key":"CIT0059","first-page":"246","volume":"170","author":"Oades GM","year":"2003","journal-title":"Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras mem-brane localization in prostate cancer cells. J Urol"},{"key":"CIT0061","first-page":"1126","volume":"84","author":"Jagdev SP","year":"2001","journal-title":"Crou-cher PI. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer"},{"doi-asserted-by":"publisher","key":"CIT0062","DOI":"10.1038\/sj.leu.2401770"},{"key":"CIT0064","first-page":"2","volume":"23","author":"Petrylak DP","year":"2004","journal-title":"Proc Am Soc Chin Oncol"},{"key":"CIT0065","first-page":"2","volume":"23","author":"Eisenberger MA","year":"2004","journal-title":"Proc Am Soc Chin Oncol"},{"key":"CIT0066","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0301-472X(01)00618-X","volume":"29","author":"Cruz JC","year":"2001","journal-title":"Exp Hematol"},{"key":"CIT0067","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1359\/jbmr.2001.16.11.2027","volume":"16","author":"Peyruchaud O","year":"2001","journal-title":"J Bone Miner Res"},{"key":"CIT0069","first-page":"5705","volume":"9","author":"Alvarez E","year":"2003","journal-title":"Chin Cancer Res"},{"issue":"1","key":"CIT0070","first-page":"S310","volume":"17","author":"Padalecki SS","year":"2002","journal-title":"Androgen deprivation causes bone loss and increased prostate cancer metastases to bone: prevention by zoledronic acid [abstract]. J Bone Miner Res"},{"key":"CIT0072","first-page":"4432","volume":"61","author":"Morony S","year":"2001","journal-title":"Cancer Res"},{"key":"CIT0073","first-page":"1235","volume":"107","author":"Zhang J","year":"2001","journal-title":"Osteoprotegerin inhibits prostate cancer-induced osteoclas-togenesis and prevents prostate tumor growth in the bone. J Clin Invest"},{"key":"CIT0074","first-page":"465","volume":"28","author":"Benford HL","year":"2001","journal-title":"Visualization of bisphosphonate-induced cas-pase-3 activity in apoptotic osteoclasts in vitro. Bone"},{"key":"CIT0075","first-page":"863","volume":"22","author":"Pickering LM","year":"2003","journal-title":"Adhesion of breast cancer cells to extracellular matrices is inhibited by zole-dronic acid and enhanced by aberrant Ras signalling [abstract]. Proc Am Soc Chin Oncol"},{"key":"CIT0076","first-page":"2708","volume":"62","author":"Virtanen SS","year":"2002","journal-title":"Cancer Res"},{"key":"CIT0077","first-page":"106","volume":"42","author":"Bonjean K","year":"2001","journal-title":"Zoledronate modulates endothelial cell surface receptors involved in angiogenesis [abstract]. Proc Am Assoc Cancer Res"},{"key":"CIT0078","first-page":"43603","volume":"278","author":"Bezzi M","year":"2003","journal-title":"Ruegg C. Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B\/Akt. J Biol Chem"},{"key":"CIT0079","first-page":"2893","volume":"9","author":"Santini D","year":"2003","journal-title":"Chin Cancer Res"}],"container-title":["Acta Oncologica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/02841860510029644","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T18:03:42Z","timestamp":1756404222000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/view\/27200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":70,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2009,7,8]]},"published-print":{"date-parts":[[2005,5]]}},"alternative-id":["10.1080\/02841860510029644"],"URL":"https:\/\/doi.org\/10.1080\/02841860510029644","relation":{},"ISSN":["0284-186X","1651-226X"],"issn-type":[{"type":"print","value":"0284-186X"},{"type":"electronic","value":"1651-226X"}],"subject":[],"published":{"date-parts":[[2005,5]]}}}